Effect of fire needle therapy on mild-moderate benign prostatic hyperplasia: Protocol for a randomized controlled pilot trial

Beijing Hospital of Traditional Chinese Medicine, Capital Medical University0 个研究点开始时间: 待定最近更新: 2023年2月20日

试验速览

暂无简介。

•1. Aged 40–80 years old;
•2. diagnosed with BPH for more than 3 months;
•3. syndrome differentiation in traditional Chinese medicine conforms to kidney yang deficiency;
•4. abstain from medication for BPH for more than 6 months before the start of treatment;
•5. IPSS score < 19 (mild-moderate BPH);
•6. Qmax<15mL/s or average flow rate (Qave)<10ml/s;
•7. with stable life signs;
•8. voluntary participation in the study and sign informed consent prior to treatment.

•1. oliguria and anuria caused by bladder or prostate malignancy, urolithiasis, acute/chronic renal failure;
•2. urinary dysfunction caused by neurogenic bladder, bladder neck fibrosis, and urethral stricture;
•3. gonorrhea and urinary tract infection;
•4. failure of invasive therapy for BPH;
•5. local organs, muscles and nerves injured by pelvic operation or trauma;
•6. abdominal aneurysms, hepatosplenomegaly, and serious cerebrovascular, cardiovascular, respiratory, digestive, hematological, or psychiatric diseases;
•7. blood coagulation disorders or requiring administration of anticoagulant medication, such as Warfarin and Dabigatran;
•8. cognitive dysfunction, psychosis, unable to cooperate with the examination and treatment.

发起方

Beijing Hospital of Traditional Chinese Medicine, Capital Medical University